Multiple myeloma and chronic leukaemias in 2014: Improved understanding of disease biology and treatment

Nature Reviews Clinical Oncology

Volumn 12, Issue 2, 2015, Pages 71-72

  San Miguel, Jesús F ^a   Kantarjian, Hagop M ^b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DASATINIB; DEXAMETHASONE; FLUDARABINE; IBRUTINIB; IDELALISIB; IMATINIB; LENALIDOMIDE; MELPHALAN; NILOTINIB; OBINUTUZUMAB; OFATUMUMAB; PLACEBO; PONATINIB; PREDNISONE; RITUXIMAB; THALIDOMIDE; ANTINEOPLASTIC AGENT;

BCR ABL GENE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CHRONIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; ONCOGENE; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MULTIPLE MYELOMA;

EID: 84961293760     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.216     Document Type: Short Survey

References (10)

1. Lohr, J. G. et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25, 91-101 (2014).
2. Mateos, M. V. et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N. Engl. J. Med. 369, 438-447 (2013).
3. Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 156, e538-e548 (2014).
4. Benboubker, L. et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N. Engl. J. Med. 371, 906-917 (2014).
5. Byrd, J. C. et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N. Engl. J. Med. 371, 213-223 (2014).
6. Furman, R. R. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370, 997-1007 (2014).
7. Goede, V. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med. 370, 1101-1110 (2014).
8. Hehlmann, R. et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study I V. J. Clin. Oncol. 32, 415-422 (2014).
9. Branford, S. et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 124, 511-518 (2014).
10. Branford, S. et al. Any BCR-ABL reduction below 10% at 6 months of therapy significantly improves outcome for CML patients with a poor response at 3 months [abstract]. Blood 122, a254 (2013).